Healthcare services M&A 2026

Healthcare services remains the most active sector in lower middle market M&A. PE backed Management Services Organizations (MSOs) are the buyer of record on most LMM dental, vet, dermatology, ophthalmology, orthopedics, cardiology, GI, and primary care deals. Strategic acquirers, regional health systems, and family offices fill the rest of the buyer pool.

The sector is not one market in 2026. Specialty subsectors with strong commercial payer mix are holding or expanding multiples. Primary care and dental are compressing. This piece walks through the dynamics that shape every healthcare services sell side process: MSO structures, multiple bifurcation, QofE requirements, and the buyer pool that owns the sector.

The MSO structure dominates LMM healthcare deals

Most US states prohibit non physician ownership of clinical practices under corporate practice of medicine laws. The MSO structure works around this by separating the clinical entity (a professional corporation owned by licensed physicians) from the management entity (the MSO, which is what the PE platform acquires).

What the MSO actually buys:

• Real estate (or assignable lease)
• Equipment and tenant improvements
• Billing infrastructure and revenue cycle management
• Brand, website, and patient acquisition systems
• Non clinical staff (admin, billing, marketing)
• The right to charge a management fee that captures the economics

What stays with the physicians:

• The professional corporation (clinical entity)
• Clinical decision making
• Direct payer contracts (depending on structure)
• Compensation governed by the MSO management agreement

Multiple bifurcation: specialty vs primary care

The headline that healthcare services multiples are down from 2022 is true on average. The story that gets missed is the bifurcation between subsectors.

Sectors holding or expanding multiples

• Orthopedics. Procedural cash flow, commercial payer concentration, ASC integration upside. Top platforms paying premium multiples for scaled groups.
• Cardiology. Procedural revenue, ancillary diagnostic upside, demand tailwinds from demographics. Multiples have held against the broader compression.
• GI. Procedural revenue, ASC integration, ancillary pathology. Strong multiples for groups with diversified procedural mix.
• Dermatology. Cash pay aesthetic services blend with medical dermatology. Platforms with established Mohs surgery and cosmetic capabilities command premium pricing.

Sectors compressing modestly

• Vet. Still active but consolidation has matured. Premium prices for practices with multiple veterinarians and growing case volume; smaller solo practices facing more buyer scrutiny.
• Optometry / ophthalmology. Bifurcated by cataract surgery volume and ASC integration. High volume cataract groups still commanding premium multiples; optometry standalone compressing.

Sectors compressing significantly

• Primary care. CMS reimbursement uncertainty, payer mix pressure, and value based care transition risk. Multiples meaningfully off the 2022 peaks.
• Dental DSOs. Mature consolidation, debt burden on the largest platforms, slowing organic growth. Add on multiples have compressed; platform deal activity has slowed.

QofE is non negotiable in healthcare services

Healthcare buyers will not sign an LOI without sell side Quality of Earnings. The sector specific issues that QofE has to address:

Payer mix concentration

The blend of commercial, Medicare, Medicaid, and self pay revenue determines sustainable margins. A practice with 60% Medicare exposure has different economics than one with 60% commercial. QofE normalizes payer mix to current rates and surfaces concentration risk by payer.

Professional services revenue normalization

Owner physician compensation often runs above market rates because it captures both labor income and equity returns. QofE separates these so the buyer sees normalized EBITDA at market physician compensation. Without this normalization, the buyer assumes the seller is overpaying themselves and adjusts the deal accordingly.

Related party transactions

Many practices have real estate owned by the physicians and leased to the practice. Lease rates may be above or below market. QofE flags these and requires resolution (lease renegotiation, real estate sale, or explicit pricing adjustment) before close.

One time items from COVID period

PPP loans, EIDL, payer advance recoupments, and pandemic period volume anomalies still appear in 3 to 5 year P&L lookbacks. QofE catches and excludes these so trailing EBITDA reflects normalized operations.

ASC integration upside

For specialty practices, ambulatory surgery center integration is a major value driver. QofE quantifies the realized vs unrealized ASC opportunity so the buyer understands what is built into projected EBITDA.

The buyer pool: who is actually closing healthcare services deals

The active LMM healthcare services buyer pool in 2026 falls into four buckets:

• PE backed MSO platforms. The largest share of LMM deal flow. Platform deal economics have compressed in primary care and dental; specialty platforms remain aggressive bidders. Each platform has a specific specialty focus and geographic appetite.
• Strategic regional players. Hospital systems, integrated delivery networks, and regional medical groups acquiring practices to extend coverage or capture referral patterns. Strategic logic, not financial engineering.
• Family offices. Increasingly active in healthcare services with a longer hold horizon than PE. Often pay competitive multiples in exchange for physician retention commitments and slower growth pace.
• Physician partnerships. Senior physicians acquiring practices from retiring partners, often using SBA financing. Smaller deal sizes, simpler structures, important buyer pool for smaller standalone practices.

What sell side advisors should know

• Sector specific banker is non negotiable. Generalist boutique IBs cost healthcare sellers money. Banker should have closed multiple deals in the same specialty in the last 18 months.
• Sell side QofE is mandatory above $10M EBITDA. Buyer side QofE will catch every issue. Surface them on the seller's timeline at $25K to $50K cost.
• Physician retention plan drives buyer interest. A 5 to 7 year physician retention commitment with rollover equity is the default expectation. Owner who wants to walk at close should plan for material price discount.
• Compliance documentation matters. Stark, Anti Kickback, HIPAA, and state specific licensure documentation is the first thing buyer counsel reviews. Get this organized before going to market.
• Real estate decision is part of the deal. Will the practice retain the building? Sell it separately? Lease back? Resolve before signing the LOI.

What founders considering exit should know

Healthcare services exits are different from generic business sales. Three things founders consistently underweight:

1. The MSO management fee structure is the deal

The headline purchase price matters less than the management fee structure that determines physician compensation post close. Negotiate the management fee methodology (percentage of collections vs percentage of EBITDA vs cost plus margin) with as much rigor as the purchase price itself. This is what determines your take home pay for the next 5 to 7 years.

2. Rollover equity has real upside but unclear timing

PE platform exit timing is rarely 5 years; it is often 7 to 10. Rollover equity is usually rolled forward in subsequent recapitalizations rather than realized at the first PE exit. Plan for longer hold than the initial deal economics suggest.

3. Junior physician partner economics matter

If the practice has multiple physicians, the deal needs to work for everyone, not just the founders. Buyers will require lock up for key producers. Front load your internal alignment conversations before going to market.

Where to read next

For the broader LMM 2026 outlook that frames where healthcare services fits, see Lower Middle Market M&A 2026 Outlook. For the QofE timeline tax that healthcare buyers always require, see Quality of Earnings on LMM Deals: The Timeline Tax. For the LOI terms specific to healthcare deals, see LOI and Exclusivity in Lower Middle Market M&A. For the data room infrastructure that supports healthcare diligence, see Sell Side Data Room Folder Structure.